ArticleInternational journal of environmental research and public health2019
Prognostic Value of
Article in International journal of environmental research and public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Retracted: Construction of a New Ferroptosis-related Prognosis Model for Survival Prediction in Colorectal CancerCurrent medicinal chemistry · 2025Article
- Prognosis and immunotherapy response prediction based on M2 macrophage-related genes in colon cancer.Journal of cancer research and clinical oncology · 2024Article
- Immune checkpoints expression patterns in early-stage triple-negative breast cancer predict prognosis and remodel the tumor immune microenvironment.Frontiers in immunology · 2023Article
- rPAC: Route based pathway analysis for cohorts of gene expression data sets.Methods (San Diego, Calif.) · 2022Article
- Identification of lymph node metastasis-related genes and patterns of immune infiltration in colon adenocarcinoma.Frontiers in oncology · 2022Article
- CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma.International journal of general medicine · 2022Article
- Establishment and verification of a prognostic tumor microenvironment-based and immune-related gene signature in colon cancer.Journal of gastrointestinal oncology · 2021Article
- Identification of prognostic immune-related gene signature associated with tumor microenvironment of colorectal cancer.BMC cancer · 2021Article
- Role of Group 1 CD1-Restricted T Cells in Host Defense and Inflammatory Diseases.Critical reviews in immunology · 2021Article
- Identification of a Tumor Microenvironment-Related Gene Signature Indicative of Disease Prognosis and Treatment Response in Colon Cancer.Oxidative medicine and cellular longevity · 2021Article
- Construction of an Immunogenomic Risk Score for Prognostication in Colon Cancer.Frontiers in genetics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cluster of differentiation (CD) antigens are cell surface markers used to differentiate haematopoietic cell types. These antigens are present in various malignancies and are reportedly linked to patient prognosis; however, they have not been implemented as prostate cancer progression markers. Here, we aimed to assess the impact of genetic variation in haematopoietic cell CD markers on clinical outcomes in patients with prostate cancer. An association study of 458 patients with prostate cancer was conducted to identify single-nucleotide polymorphisms in 11 candidate CD marker genes associated with biochemical recurrence (BCR) after radical prostatectomy. Identified predictors were further evaluated in an additional cohort of 185 patients. Joint population analyses showed that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.